Lifibrol and its use

US5493051A · kind A · utility

Assignee

• Klinge Pharma GmbH · DE

Inventors

• Artur Burger · Innsbruck, AT
• Anita Lettenbichler · Innsbruck, AT
• Fritz Stanislaus · Munich, DE
• Arnim Laicher · Hersbruck, DE
• Karl Schwitzer · Hersbruck, DE
• Axel Woschina · Poing, DE

Key dates

• Filing date: Apr 29, 1994
• Grant date: Feb 20, 1996
• Expiry date: Apr 29, 2014

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P3/06
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

A new modification of Lifibrol is described with a melting point of 132.degree. C.-138.degree. C. particularly from 134.degree. C.-136.degree. C. and a primary peak in an IR spectrum at a wave number of 3,200-3,400, preferably 3,250-3,350. The new modification of Lifibrol (modification II) is distinguished in that it allows for good crystallization and, therefore, can be formulated without problems on a large industrial scale for tablets of acceptable size and high stability.